These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2477048)

  • 41. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
    Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
    J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
    O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
    J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi e Leucenie (GIMURELL) study.
    Cabras MG; Mamusa AM; Vitolo U; Freilone R R; Dessalvi P; Orsucci L; Tonso A; Levis A; Liberati M; Lay G; Angelucci E
    Leuk Lymphoma; 2009 Sep; 50(9):1475-81. PubMed ID: 19579074
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A cooperative study on ProMACE-CytaBOM in aggressive non-Hodgkin's lymphomas.
    Cassi E; Butti C; Baldini L; Pisoni GB; Ceriani A; Confalonieri C; Scandolaro L; De Paoli A; Lombardi F; Montalbetti L
    Leuk Lymphoma; 1994 Mar; 13(1-2):111-8. PubMed ID: 7517742
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
    Gordon LI; Anderson J; Habermann TM; Winter JN; Glick J; Schilder RJ; Cassileth P
    J Clin Oncol; 1996 Apr; 14(4):1275-81. PubMed ID: 8648384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
    J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CODBLAM IV chemotherapy for large cell lymphoma: sequential use of infusional vincristine and bleomycin and "high dose" consolidation.
    Rafi S; Coleman M; Kaufmann T; Cesarman G; Papish SW; Bernhart B; Gaynor M; Reisman AM
    Am J Clin Oncol; 1997 Feb; 20(1):90-6. PubMed ID: 9020298
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.
    Herbrecht R; Ortiz S; Damonte JC; Liu KL; Maloisel F; Dufour P; Bergerat JP; Oberling F
    Hematol Oncol; 1991; 9(4-5):253-7. PubMed ID: 1720760
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
    Fridrik MA; Hausmaninger H; Linkesch W; Stöger M; Sill H; Neubauer M; Seewann HL; Klocker J; Haidinger R; Schiller L; Pont J; Raudaschl G; Falk M; Radaszkiewicz T
    J Clin Oncol; 1996 Jan; 14(1):227-32. PubMed ID: 8558202
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG).
    Chisesi T; Santini G; Capnist G; Coser P; Contu A; Porcellini A; Rizzoli V; Sertoli M; Rancan L; Salvagno L
    Leukemia; 1991; 5 Suppl 1():107-11. PubMed ID: 1716334
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
    Bosly A; Lepage E; Coiffier B; Fillet G; Herbrecht R; Divine M; Dupriez B; Nouvel C; Deconninck E; Tilly H; Bordessoule D; Gaulard P; Gisselbrecht C;
    Hematol J; 2001; 2(4):279-85. PubMed ID: 11920261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma.
    De Lord C; Newland AC; Linch DC; Vaughan Hudson B; Vaughan Hudson G
    Hematol Oncol; 1992; 10(2):81-6. PubMed ID: 1592365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients.
    Todeschini G; Ambrosetti A; Meneghini V; Pizzolo G; Menestrina F; Chilosi M; Benedetti F; Veneri D; Cetto GL; Perona G
    J Clin Oncol; 1990 May; 8(5):804-8. PubMed ID: 1692089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
    McLaughlin P; Hagemeister FB; Swan F; Cabanillas F; Romaguera J; Rodriguez MA; Lee MS; Pate O; Sarris A; Younes A
    Ann Oncol; 1994; 5 Suppl 2():73-7. PubMed ID: 7515650
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.
    Somers R; Carde P; Thomas J; Tirelli U; Keuning JJ; Bron D; Delmer A; de Bock R; De Wolf-Peeters C; Keunig JJ
    Ann Oncol; 1994; 5 Suppl 2():85-9. PubMed ID: 7515651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Failure of conventional chemotherapy in aggressive lymphomas.
    Cunningham D; Hepplestone A; Gilchrist NL; Dagg JH; Evans IL; Soukop M
    Postgrad Med J; 1987 Jan; 63(735):11-5. PubMed ID: 2444960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.